In contrast, a lysine‐to‐glutamic acid substitution, K650E, in the kinase domain of FGFR3, found in a small number of bladder tumours (∼1% of all mutations), exaggerates ligand‐dependent kinase activation. Here, FGFR3 is linked to urinary bladder neoplasm.